# Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation

> **NCT03475212** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Pediatric Transplantation & Cellular Therapy Consortium** · enrollment: 52 (actual)

## Conditions studied

- Cytomegalovirus Infections
- Adenovirus Infection
- EBV Infection

## Interventions

- **BIOLOGICAL:** Virus Specific T-cell (VST) infusion

## Key facts

- **NCT ID:** NCT03475212
- **Lead sponsor:** Pediatric Transplantation & Cellular Therapy Consortium
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-06-20
- **Primary completion:** 2025-06-30
- **Final completion:** 2025-06-30
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2025-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03475212

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03475212, "Antiviral Cellular Therapy for Enhancing T-cell Reconstitution Before or After Hematopoietic Stem Cell Transplantation". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03475212. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*